On August 16, 2024 Nuntius Therapeutics reported a strategic collaboration agreement with Japan’s Taiho Pharmaceutical to develop next-generation messenger ribonucleic acid (mRNA) cancer immunotherapies (Press release, Nuntius Therapeutics, AUG 16, 2024, View Source [SID1234646069]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership will leverage Nuntius’ nanocarrier technologies, which have shown potential in targeting cell types beyond the liver, a significant advancement in mRNA delivery.

This collaboration follows a successful feasibility study that demonstrated the capabilities of Nuntius’ cell-specific peptide dendrimer- and lipid-based nanocarriers.

Nuntius Therapeutics CEO and co-founder Benita Nagel said: "We are thrilled to embark on this collaboration with Taiho to improve treatments for cancer patients. Taiho is an excellent partner for us given their strong oncology-focused research and commercial capabilities."

The company’s programmable and scalable nanocarriers may work on cell types other than the liver and surpass current delivery technologies.